Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
May 4, 2022 4:05 PM EDTTotal revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2022.
... More